Study of CS0159 for primary biliary cholangitis with poor UDCA response
Part of Digestive system clinical trials.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary biliary cholangitis (PBC) based on blood tests or a liver biopsy.
- You have taken UDCA for at least 6 months but it didn't work well enough, or you couldn't take it due to side effects.
- Your blood test shows high alkaline phosphatase (ALP) levels (at least 1.67 times the normal upper limit).
- Your liver enzymes (ALT, AST) and bilirubin are within certain safe limits.
- You are between 18 and 75 years old and willing to use effective birth control.
- You have not had serious liver complications like variceal bleeding, ascites, or encephalopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.